PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

Reset

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Heart failure (Ivabradine - Heart failure)

Records returned : 28 (on 21 Nov 2024 at 18:04:49). .

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
02.06.03
Ivabradine
Heart failure
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Restricted to initiation by cardiology only. Transfer of prescribing to primary care only after initiation and at least the first month supply from the specialist.
02.05.05
Ramipril
Heart failure
Green
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Preferred
02.05.05
Captopril
Heart failure
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
02.05.05
Enalapril maleate
Heart failure
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
02.05.05
Lisinopril
Heart failure
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
02.05.05
Perindopril erbumine
Heart failure
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
2mg, 4mg and 8mg tablets. Do not prescribe as perindopril arginine.
02.04.00
Bisoprolol fumarate
Heart failure
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Preferred
02.04.00
Carvedilol
Heart failure
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
02.05.05
04.07.04
Candesartan cilexetil
Heart failure
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Preferred
Preferred angiotensin II receptor blocker.
02.05.05
Losartan potassium
Heart failure
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
02.05.05
Valsartan
Heart failure
Green
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
02.02.03
Spironolactone
Heart failure
Green
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Preferred
Spironolactone is the preferred aldosterone antagonist for all stages of heart failure.
02.05.04
07.04.01
Prazosin hydrochloride
Heart failure
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Co-amilozide (Amiloride hydrochloride/hydrochlorot
Heart failure
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
02.01.01
Digoxin
Heart failure
Green
Formulations :
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
ONE 62.5microgram tablet is approximately equivalent to 50microgram (1mL) elixir
02.02.03
Eplerenone
Heart failure
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Initiation restricted to cardiology. Transfer to primary care only after initiation and at least the first month supply from the specialist.
06.01.02
Dapagliflozin
Heart failure
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
06.01.02
Empagliflozin
Heart failure
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
02.04.00
Nebivolol
Heart failure
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Prescribing in primary care on specialist recommendation.
02.05.01
Hydralazine hydrochloride
Heart failure
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Transfer of prescribing to primary care only after initiation and stabilisation by the specialist.
02.02.01
Metolazone
Heart failure
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
SA
Important
Initiation by specialist. The licensed (Xaqua) and unlicensed (Zaroxolyn) tablets have different bioavailabilities. These products are not interchangable=Prescribe by Brand
02.05.05
Sacubitril/valsartan
Heart failure
Amber
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
SA
Important
Do not co-administer with an ACEi or ARB due to risk of angioedema.
02.02.01
11.06.00
Acetazolamide
Heart failure
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Un
Important
Off label. Acutely decompensated heart failure. RSCH Cardiology only
Levosimendan
Heart failure
Red
Formulations :
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
U
Important
Acutely decompensated heart failure. Unlicensed. Restricted to cardiology / ICU only. Use according to protocol
02.01.02
Enoximone
Heart failure
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
02.01.02
Milrinone lactate
Heart failure
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Un
Important
Restricted use: ITU only at SASH Consultants only at RSCH
02.05.05
Enalapril maleate
Heart failure
Non Formulary
Formulations :
  • Oro-dispersible
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Only licensed for use in children.
02.05.05
Sacubitril/valsartan
Heart failure
Non Formulary
Formulations :
  • Granules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Do not co-administer with an ACEi or ARB due to risk of angioedema.
Only licensed for use in children.
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq
BlueTeq form to be completed
NICE
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More